miR-4721, Induced by EBV-miR-BART22, Targets GSK3β to Enhance the Tumorigenic Capacity of NPC through the WNT/β-catenin Pathway
Author(s) -
Zibo Tang,
WeiFeng Chen,
Yan Xu,
Xian Lin,
Xiong Liu,
YongHao Li,
Yiyi Liu,
Zhijian Luo,
Zhen Liu,
Weiyi Fang,
Mengyang Zhao
Publication year - 2020
Publication title -
molecular therapy — nucleic acids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.208
H-Index - 59
ISSN - 2162-2531
DOI - 10.1016/j.omtn.2020.09.021
Subject(s) - nasopharyngeal carcinoma , cancer research , wnt signaling pathway , cell cycle , oncogene , protein kinase b , pi3k/akt/mtor pathway , biology , tumor progression , cell growth , catenin , signal transduction , cell , cancer , microbiology and biotechnology , medicine , genetics , radiation therapy
Nasopharyngeal carcinoma (NPC) is prevalent in East and Southeast Asia. In a previous study, Epstein-Barr virus (EBV)-miR-BART22 induces tumor metastasis and stemness and is significantly involved in NPC progression. In the present study, we observed that miR-4721 is induced by EBV-miR-BART22 through phosphatidylinositol 3-kinase (PI3K)/AKT/c-JUN/Sp1 signaling to promote its transcription. In a subsequent study, we observed that miR-4721 serves as a potential oncogenic factor promoting NPC cell cycle progression and cell proliferation in vitro and in vivo . Mechanism analysis indicated that miR-4721 directly targetes GSK3β and reduces its expression, which therefore elevates β-catenin intra-nuclear aggregation and activates its downstream cell cycle factors, including CCND1 and c-MYC. In clinical samples, miR-4721 and GSK3β are respectively observed to be upregulated and downregulated in NPC progression. Elevated expression of miR-4721 is positively associated with clinical progression and poor prognosis. Our study first demonstrated that miR-4721 as an oncogene is induced by EBV-miR-BART22 via modulating PI3K/AKT/c-JUN/Sp1 signaling to target GSK3β, which thus activates the WNT/β-catenin-stimulated cell cycle signal and enhances the tumorigenic capacity in NPC. miR-4721 may be a potential biomarker or therapeutic target in NPC treatment in the future.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom